---
reference_id: "PMID:32101663"
title: Pembrolizumab for Early Triple-Negative Breast Cancer.
authors:
- Schmid P
- Cortes J
- Pusztai L
- McArthur H
- Kümmel S
- Bergh J
- Denkert C
- Park YH
- Hui R
- Harbeck N
- Takahashi M
- Foukakis T
- Fasching PA
- Cardoso F
- Untch M
- Jia L
- Karantza V
- Zhao J
- Aktan G
- Dent R
- "O'Shaughnessy J"
- KEYNOTE-522 Investigators
journal: N Engl J Med
year: '2020'
doi: 10.1056/NEJMoa1910549
content_type: abstract_only
---

# Pembrolizumab for Early Triple-Negative Breast Cancer.
**Authors:** Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J, KEYNOTE-522 Investigators
**Journal:** N Engl J Med (2020)
**DOI:** [10.1056/NEJMoa1910549](https://doi.org/10.1056/NEJMoa1910549)

## Content

1. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P(1), Cortes J(1), Pusztai L(1), McArthur H(1), Kümmel S(1), Bergh J(1), 
Denkert C(1), Park YH(1), Hui R(1), Harbeck N(1), Takahashi M(1), Foukakis T(1), 
Fasching PA(1), Cardoso F(1), Untch M(1), Jia L(1), Karantza V(1), Zhao J(1), 
Aktan G(1), Dent R(1), O'Shaughnessy J(1); KEYNOTE-522 Investigators.

Collaborators: Antill Y, Baron-Hay S, Hui R, Inglis PL, Murray N, Thomson J, 
Tsoi D, Barrios CHE, Da Cunha AD Jr, de Cassia Costamilan R, de Figueiredo 
Chaves F, de Freitas R Jr, Girotto GC, Linck RDM, Pedrini JL, Skare NG, Boileau 
JF, Cescon D, Pavic M, Provencher L, Robidoux A, Song X, Verma S, Avendano Rojas 
AC, Bruges R, Gonzalez Fernandez ME, Montoya Restrepo ME, Rojas LL, Sanchez JO, 
Rojas-Uribe GA, Bourgeois H, Chieze S, Chocteau-Bouju D, Dalenc F, Delbaldo C, 
Dohollou N, Giacchetti S, Levy C, Loiret D, Sablin MP, Mansi L, Mouret-Reynier 
MA, Deryal M, Fasching PA, Harbeck N, Hartkopf A, Kurbacher CM, Reinisch M, 
Thomssen C, Untch M, Witzel I, Murphy C, Walshe J, Geffen D, Tokar M, Katz D, 
Paluch-Shimon S, Kaufman B, Peretz-Yablonski T, Ryvo L, Evron E, Wolf I, Stemmer 
S, Baldini E, Beneditti G, Battelli N, Colleoni M, De Laurentis M, Pedersini R, 
Rocco A, Hattori M, Iwata H, Hayashi N, Inoue K, Komoike Y, Masuda N, Miyoshi Y, 
Mukai H, Ohno S, Ohtani S, Saeki T, Osaki A, Sagara Y, Shimizu C, Tamura K, 
Takahashi M, Takano T, Tokuda Y, Niikura N, Tsugawa K, Watanabe J, Yamamoto N, 
Yamamoto Y, Bauer-Kosinska B, Chmielowska E, Chrzanowska-Kapica A, 
Grela-Wojewoda A, Kmak KL, Danielewicz I, Lacko A, Tarnawski R, Zurawski B, 
Cardoso F, Ferreira M, Sousa R, Dionisi MR, Fadeeva NV, Krivorotko PV, 
Lichinitser MR, Ganshina I, Lipatov ON, Mukhametshina GZ, Nechaeva MN, Shomova 
MV, Dent R, Ahn JH, Im SA, Kim GM, Park YH, Albanell J, Bofill FJS, de Las Heras 
BB, Gonzalez Cortijo L, Holgado E, Gion M, Lopez Lopez R, Morilla Ruiz I, 
Villanueva R, Munoz Couselo E, Zamora Adelantado E, Perez Garcia JM, Andersson 
A, Foukakis T, Hallbeck AL, Lindman H, Chang YC, Chen SC, Huang CS, Lee KT, Liu 
MC, Tseng LM, Abali H, Aksoy S, Arslan C, Basaran G, Cicin I, Keskin S, Mandel 
NM, Oksuzoglu B, Ozdemir E, Ozdogan M, Ozguroglu M, Ozyilkan O, Uslu RF, Gokmen 
E, Yucel I, Yilmaz B, Chan S, Graham J, Harper-Wynne C, Kyle F, Mukesh MB, 
Schmid P, Wheatley D, Ali H, Andersen JC, Battelli C, Bruetman DG, Kio E, Chang 
J, Chaudhry A, Danso M, Denduluri N, Robinson Diamond J, Dillon P, Guarino MJ, 
Haley BB, Harris RP, Holmes FA, Cairo M, Irvin WJ, Jankowitz R, Emens LA, Jones 
VE, Leone J, Phadke S, Lopresti M, MacLaughlin W, McArthur H, Mehta A, Nanda R, 
Oliff IA, O'Shaughnessy JA, Page D, Patt DA, Pusztai L, Richards DA, Rybalova I, 
Sachdev J, Saha P, Specht J, Stampleman L, Stokoe CTF, Swart R, Thara E, 
Toppmeyer DL, Tsai M, Valdes-Albini F, Vidal G, Ward P, Weyburn TD, Chung EK, 
Wilks ST, Harroff A, Zhuo Y.

Author information:
(1)From Barts Cancer Institute, Queen Mary University of London, London (P.S.); 
International Oncology Bureau Institute of Oncology, Quirón Group, Madrid, and 
Vall d'Hebron Institute of Oncology, Barcelona (J.C.) - both in Spain; Yale 
School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); Cedars-Sinai 
Medical Center, Los Angeles (H.M.); Kliniken Essen-Mitte, Essen (S.K.), the 
Institute of Pathology, Philipps-University Marburg and University of Marburg, 
Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and 
Comprehensive Cancer Center Ludwig Maximilian University of Munich, University 
of Munich, Munich (N.H.), University Hospital Erlangen, Department of Gynecology 
and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan 
Region of Nuremberg, Erlangen (P.A.F.), and the Breast Cancer Center, Helios 
Klinikum Berlin-Buch, Berlin (M.U.) - all in Germany; the Department of 
Oncology-Pathology, Karolinska Institutet and Breast Cancer Center, Theme 
Cancer, Karolinska University Hospital, Solna, Sweden (J.B., T.F.); Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 
(Y.H.P.); Westmead Breast Cancer Institute, Westmead Hospital and the University 
of Sydney, Sydney (R.H.); Department of Breast Surgery, National Hospital 
Organization Hokkaido Cancer Center, Sapporo, Japan (M.T.); the Breast Unit, 
Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal (F.C.); 
Merck, Kenilworth, NJ (L.J., V.K., J.Z., G.A.); the National Cancer Center 
Singapore, Duke-National University of Singapore Medical School, Singapore 
(R.D.); and Baylor University Medical Center, Texas Oncology and US Oncology, 
Dallas (J.O.).

Comment in
    Nat Rev Clin Oncol. 2020 Apr;17(4):196. doi: 10.1038/s41571-020-0349-3.
    Lancet Oncol. 2020 Apr;21(4):e183. doi: 10.1016/S1470-2045(20)30154-6.
    Strahlenther Onkol. 2020 Sep;196(9):841-843. doi: 
10.1007/s00066-020-01641-9.
    N Engl J Med. 2020 Jun 25;382(26):e108. doi: 10.1056/NEJMc2006684.
    Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):377-381. doi: 
10.1016/j.ijrobp.2022.05.024.

BACKGROUND: Previous trials showed promising antitumor activity and an 
acceptable safety profile associated with pembrolizumab in patients with early 
triple-negative breast cancer. Whether the addition of pembrolizumab to 
neoadjuvant chemotherapy would significantly increase the percentage of patients 
with early triple-negative breast cancer who have a pathological complete 
response (defined as no invasive cancer in the breast and negative nodes) at 
definitive surgery is unclear.
METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 
with previously untreated stage II or stage III triple-negative breast cancer to 
receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 
mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the 
pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and 
carboplatin (390 patients; the placebo-chemotherapy group); the two groups then 
received an additional four cycles of pembrolizumab or placebo, and both groups 
received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After 
definitive surgery, the patients received adjuvant pembrolizumab or placebo 
every 3 weeks for up to nine cycles. The primary end points were a pathological 
complete response at the time of definitive surgery and event-free survival in 
the intention-to-treat population.
RESULTS: At the first interim analysis, among the first 602 patients who 
underwent randomization, the percentage of patients with a pathological complete 
response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the 
pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the 
placebo-chemotherapy group (estimated treatment difference, 13.6 percentage 
points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months 
(range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the 
pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the 
placebo-chemotherapy group had disease progression that precluded definitive 
surgery, had local or distant recurrence or a second primary tumor, or died from 
any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment 
phases, the incidence of treatment-related adverse events of grade 3 or higher 
was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the 
placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 
patient), respectively.
CONCLUSIONS: Among patients with early triple-negative breast cancer, the 
percentage with a pathological complete response was significantly higher among 
those who received pembrolizumab plus neoadjuvant chemotherapy than among those 
who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & 
Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, 
NCT03036488.).

Copyright © 2020 Massachusetts Medical Society.

DOI: 10.1056/NEJMoa1910549
PMID: 32101663 [Indexed for MEDLINE]